FDA Classifies Opioid-Induced Impairment Monitor as Class II with Special Controls, Enhancing Access to Innovation

What this means for your practice

This classification by the FDA represents a positive development for healthcare practices, particularly those involved in pain management, post-operative care, or any setting where opioids are administered. By placing the monitor for opioid induced impairment of oxygenation into Class II, the FDA has streamlined its regulatory pathway. This means that while these devices will still undergo special controls to ensure safety and effectiveness, the burden on manufacturers to bring them to market is reduced compared to a Class III designation. For telehealth brands, this could facilitate the integration of remote patient monitoring solutions for patients on opioid therapy, improving patient safety and outcomes by providing timely alerts for oxygen impairment. Medspas, dental practices, and chiropractic offices that may administer sedatives or analgesics, or manage patients on opioid prescriptions, could also benefit from the increased availability and potentially lower cost of these monitoring devices. The establishment of a predicate device through this De Novo classification also signals a clearer path for future innovations in this critical area of patient safety.

Washington D.C. — The Food and Drug Administration (FDA) has announced a final rule classifying the monitor for opioid induced impairment of oxygenation into Class II, subject to special controls. This regulatory action, effective June 30, 2026, is a significant step aimed at ensuring the safety and effectiveness of these devices while simultaneously fostering innovation and enhancing patient access.

Understanding the Classification

Medical devices in the United States are categorized into three regulatory classes—Class I, II, or III—based on the level of control necessary to provide reasonable assurance of their safety and effectiveness. Class I devices present the lowest risk, while Class III devices present the highest risk and typically require premarket approval (PMA).

The monitor for opioid induced impairment of oxygenation, as a new device type not in commercial distribution before May 28, 1976, was initially subject to automatic classification into Class III by operation of law. This automatic assignment occurs regardless of the actual risk posed by the device and requires extensive premarket approval processes, which can be time-consuming and resource-intensive for manufacturers.

The De Novo Classification Process

To address situations where a new device does not fit into an existing classification or when an automatic Class III designation is unwarranted for a low-to-moderate risk device, the FDA employs the “De Novo” classification process. This pathway, authorized under section 513(f)(2) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), allows the FDA to classify a device into Class I or II if it determines that general and/or special controls alone are sufficient to provide reasonable assurance of safety and effectiveness.

There are two main procedures for De Novo classification:

1. First Procedure: A device sponsor initially submits a premarket notification (510(k)) for a new device. After receiving an order from FDA classifying the device into Class III, the sponsor then requests a De Novo classification. 2. Second Procedure: If a sponsor determines there is no legally marketed device upon which to base a determination of substantial equivalence (a requirement for 510(k)), they can directly request a De Novo classification.

In this specific case, the FDA received Masimo Corporation's request for De Novo classification of the Masimo SafetyNet Opioid System on February 19, 2020. Through this process, the FDA classified the device into Class II. This means that while general controls apply, additional

Key Facts

| Detail | Value | |---|---| | Agency | Food and Drug Administration (FDA), HHS | | Action | Final amendment; final order | | Device Type | Monitor for opioid induced impairment of oxygenation | | Classification | Class II (special controls) | | Effective Date | June 30, 2026 | | Classification Applicable Date | March 31, 2023 | | Docket Number | FDA-2026-N-6707 |

Frequently Asked Questions

What specific device type has the FDA classified?

The FDA has classified the monitor for opioid induced impairment of oxygenation.

What class has the FDA assigned to this device type?

The FDA has classified this device type into Class II with special controls.

Why did the FDA classify this device into Class II?

The FDA classified the device into Class II because it determined that this classification will provide a reasonable assurance of the device's safety and effectiveness, and will enhance patient access to beneficial innovative devices by reducing regulatory burdens.

What is the 'De Novo' classification process mentioned?

The De Novo process is a pathway for the FDA to classify new devices into Class I or II that were automatically placed into Class III by operation of law and for which no predicate device exists.

How does this classification benefit other device manufacturers?

Once a device is classified into Class I or II via the De Novo process, it can serve as a predicate for future substantially equivalent devices, allowing other manufacturers to use the less burdensome 510(k) process instead of a De Novo request or premarket approval.

Source: FDA — Rule: Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of Oxygenation · 2026-06-30